A detailed history of Strategic Blueprint, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Strategic Blueprint, LLC holds 3,418 shares of GILD stock, worth $227,946. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,418
Previous 3,971 13.93%
Holding current value
$227,946
Previous $321,000 22.12%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$71.58 - $87.29 $39,583 - $48,271
-553 Reduced 13.93%
3,418 $250,000
Q4 2023

Jan 25, 2024

SELL
$73.27 - $83.09 $30,553 - $34,648
-417 Reduced 9.5%
3,971 $321,000
Q3 2023

Oct 18, 2023

BUY
$73.94 - $80.67 $24,252 - $26,459
328 Added 8.08%
4,388 $328,000
Q2 2023

Oct 18, 2023

BUY
$76.01 - $86.7 $1,976 - $2,254
26 Added 0.64%
4,060 $312,000
Q1 2023

Apr 28, 2023

BUY
$77.31 - $88.08 $32,006 - $36,465
414 Added 11.44%
4,034 $334,000
Q4 2022

Jan 26, 2023

BUY
$62.32 - $89.47 $225,598 - $323,881
3,620 New
3,620 $0
Q2 2022

Aug 12, 2022

SELL
$57.72 - $65.01 $205,194 - $231,110
-3,555 Closed
0 $0
Q1 2022

Aug 12, 2022

BUY
$57.92 - $72.58 $205,905 - $258,021
3,555 New
3,555 $211,000
Q3 2021

Nov 12, 2021

SELL
$67.69 - $73.03 $22,608 - $24,392
-334 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$63.47 - $69.35 $21,198 - $23,162
334 New
334 $22,000
Q2 2020

Jul 20, 2020

SELL
$72.34 - $84.0 $246,245 - $285,936
-3,404 Closed
0 $0
Q1 2020

Apr 20, 2020

BUY
$62.63 - $80.22 $213,192 - $273,068
3,404 New
3,404 $254,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $83.6B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Strategic Blueprint, LLC Portfolio

Follow Strategic Blueprint, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Blueprint, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Strategic Blueprint, LLC with notifications on news.